| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10112903 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(6 years from now) | |
| US8431576 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Oct, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8796276 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(6 years from now) | |
| US10849894 | ALKERMES INC | Aripiprazole prodrug composition |
Aug, 2035
(11 years from now) | |
| US10688091 | ALKERMES INC | Aripiprazole prodrug composition |
Aug, 2035
(11 years from now) | |
| US11154552 | ALKERMES INC | Aripiprazole prodrug composition |
Aug, 2035
(11 years from now) | |
| US10016415 | ALKERMES INC | Aripiprazole prodrug compositions |
Sep, 2035
(11 years from now) | |
| US11273158 | ALKERMES INC | Aripiprazole dosing strategy |
Apr, 2039
(14 years from now) | |
Aristada Initio Kit is owned by Alkermes Inc.
Aristada Initio Kit contains Aripiprazole Lauroxil.
Aristada Initio Kit has a total of 8 drug patents out of which 0 drug patents have expired.
Aristada Initio Kit was authorised for market use on 29 June, 2018.
Aristada Initio Kit is available in suspension, extended release;intramuscular dosage forms.
Aristada Initio Kit can be used as treatment of schizophrenia.
Drug patent challenges can be filed against Aristada Initio Kit from 06 October, 2019.
The generics of Aristada Initio Kit are possible to be released after 06 April, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2020 |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
NCE-1 date: 06 October, 2019
Market Authorisation Date: 29 June, 2018
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ARISTADA INITIO KIT family patents
